BioInfra Co., Ltd. (KOSDAQ:199730)

Market Cap	19.38B -35.7%
Revenue (ttm)	23.15B -2.9%
Net Income	-9.13B
EPS	-1,877.00
Shares Out	4.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	300.00 (7.57%)
Ex-Dividend Date	Dec 29, 2025

Volume	5,570
Average Volume	9,177
Open	3,995.00
Previous Close	3,995.00
Day's Range	3,860.00 - 3,995.00
52-Week Range	3,200.00 - 6,490.00
Beta	0.41
RSI	38.60
Earnings Date	n/a

About BioInfra

BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of gener...

• Industry: Commercial Physical and Biological Research
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 199730

Financial Performance

In 2025, BioInfra's revenue was 23.15 billion, a decrease of -2.87% compared to the previous year's 23.83 billion. Losses were -9.13 billion, 129.7% more than in 2024.